Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017

Adam J. Rose; Jaclyn M.W. Hughto; Michael S. Dunbar; Emily K. Quinn; Madeline Deutsch; Jamie Feldman; Asa Radix; Joshua D. Safer; Jillian C. Shipherd; Julie Thompson; Guneet K. Jasuja

doi:10.1089/trgh.2021.0041

Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017

Adam J. Rose^*, Jaclyn M.W. Hughto, Michael S. Dunbar, Emily K. Quinn, Madeline Deutsch, Jamie Feldman, Asa Radix, Joshua D. Safer, Jillian C. Shipherd, Julie Thompson, Guneet K. Jasuja

^*Corresponding author for this work

Department of Health Policy, Economics and Administration

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Combination therapy with estrogen and spironolactone may help some transgender women achieve desired results. We used two databases, OptumLabs® Data Warehouse (OLDW) and Veterans Health Administration (VHA), to examine trends in feminizing therapy. We included 3368 transgender patients from OLDW and 3527 from VHA, all of whom received estrogen, spironolactone, or both between 2006 and 2017. In OLDW, the proportion receiving combination therapy increased from 47% to 75% during this period. Similarly, in VHA, the proportion increased from 39% to 69% during this period. We conclude that the use of combination hormone therapy has become much more common over the past decade.

Original language	English
Pages (from-to)	188-194
Number of pages	7
Journal	Transgender Health
Volume	8
Issue number	2
DOIs	https://doi.org/10.1089/trgh.2021.0041
State	Published - 1 Apr 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023, Mary Ann Liebert, Inc.

Keywords

aldosterone antagonists
drug therapy
hormones
transgender persons

Access to Document

10.1089/trgh.2021.0041

Cite this

@article{3ae98cb5ba684b85866c6f3e5c125262,

title = "Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017",

abstract = "Combination therapy with estrogen and spironolactone may help some transgender women achieve desired results. We used two databases, OptumLabs{\textregistered} Data Warehouse (OLDW) and Veterans Health Administration (VHA), to examine trends in feminizing therapy. We included 3368 transgender patients from OLDW and 3527 from VHA, all of whom received estrogen, spironolactone, or both between 2006 and 2017. In OLDW, the proportion receiving combination therapy increased from 47% to 75% during this period. Similarly, in VHA, the proportion increased from 39% to 69% during this period. We conclude that the use of combination hormone therapy has become much more common over the past decade.",

keywords = "aldosterone antagonists, drug therapy, hormones, transgender persons",

author = "Rose, {Adam J.} and Hughto, {Jaclyn M.W.} and Dunbar, {Michael S.} and Quinn, {Emily K.} and Madeline Deutsch and Jamie Feldman and Asa Radix and Safer, {Joshua D.} and Shipherd, {Jillian C.} and Julie Thompson and Jasuja, {Guneet K.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2023, Mary Ann Liebert, Inc.",

year = "2023",

month = apr,

day = "1",

doi = "10.1089/trgh.2021.0041",

language = "אנגלית",

volume = "8",

pages = "188--194",

journal = "Transgender Health",

issn = "2380-193X",

publisher = "Mary Ann Liebert Inc.",

number = "2",

}

TY - JOUR

T1 - Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017

AU - Rose, Adam J.

AU - Hughto, Jaclyn M.W.

AU - Dunbar, Michael S.

AU - Quinn, Emily K.

AU - Deutsch, Madeline

AU - Feldman, Jamie

AU - Radix, Asa

AU - Safer, Joshua D.

AU - Shipherd, Jillian C.

AU - Thompson, Julie

AU - Jasuja, Guneet K.

PY - 2023/4/1

Y1 - 2023/4/1

N2 - Combination therapy with estrogen and spironolactone may help some transgender women achieve desired results. We used two databases, OptumLabs® Data Warehouse (OLDW) and Veterans Health Administration (VHA), to examine trends in feminizing therapy. We included 3368 transgender patients from OLDW and 3527 from VHA, all of whom received estrogen, spironolactone, or both between 2006 and 2017. In OLDW, the proportion receiving combination therapy increased from 47% to 75% during this period. Similarly, in VHA, the proportion increased from 39% to 69% during this period. We conclude that the use of combination hormone therapy has become much more common over the past decade.

AB - Combination therapy with estrogen and spironolactone may help some transgender women achieve desired results. We used two databases, OptumLabs® Data Warehouse (OLDW) and Veterans Health Administration (VHA), to examine trends in feminizing therapy. We included 3368 transgender patients from OLDW and 3527 from VHA, all of whom received estrogen, spironolactone, or both between 2006 and 2017. In OLDW, the proportion receiving combination therapy increased from 47% to 75% during this period. Similarly, in VHA, the proportion increased from 39% to 69% during this period. We conclude that the use of combination hormone therapy has become much more common over the past decade.

KW - aldosterone antagonists

KW - drug therapy

KW - hormones

KW - transgender persons

UR - http://www.scopus.com/inward/record.url?scp=85152743239&partnerID=8YFLogxK

U2 - 10.1089/trgh.2021.0041

DO - 10.1089/trgh.2021.0041

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 37013092

AN - SCOPUS:85152743239

SN - 2380-193X

VL - 8

SP - 188

EP - 194

JO - Transgender Health

JF - Transgender Health

IS - 2

ER -

Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this